Presentation of Research Achievements in Liver Transplantation and New Insights into Liver Transplantation Progress

Presentation of Research Achievements in Liver Transplantation and New Insights into Liver Transplantation Progress

From November 10th to 14th, 2023, the annual grand event in the field of hepatology, the American Association for the Study of Liver Diseases Annual Meeting (AASLD2023), took place in Boston, USA. The on-site reporting team of "Hepatology Digest" had the privilege of inviting Dr. Wei Rao's team from the Organ Transplant Center of Qingdao University Affiliated Hospital, to introduce the team's achievements, share their experiences at the conference, and discuss future research directions. The interview content is shared below.
Professor Lili Liu and Associate Researcher Xuejing Zou’s Team: Targeting Macrophages May Offer New Treatment Strategies for IInhibiting MASH Progres

Professor Lili Liu and Associate Researcher Xuejing Zou’s Team: Targeting Macrophages May Offer New Treatment Strategies for IInhibiting MASH Progres

The AASLD 2023 Annual Meeting, hosted by the American Association for the Study of Liver Diseases, recently concluded in Boston, USA. A team led by Professor Lili Liu and Associate Researcher Xuejing Zou from Southern Medical University's Nanfang Hospital in China, including Physician Ziyong Zhang, presented their research in the field of Metabolism-Associated Steatohepatitis (MASH) during the conference's oral presentations (Oral 38). Their study suggests that targeting macrophages may offer a new strategy to inhibit the progression of MASH to liver fibrosis. Dr. Ziyong Zhang was invited to introduce their research at the conference and share his experiences and insights.
Dr. Jessica Seidelman: Implementation of a blood culture algorithm in emergency department patients as a diagnostic stewardship intervention

Dr. Jessica Seidelman: Implementation of a blood culture algorithm in emergency department patients as a diagnostic stewardship intervention

Blood culture is one of the most important tests in the clinical microbiology laboratory. Blood culture is the gold standard for diagnosing bloodstream infection and bacteremia. However, in the United States, blood cultures are still performed even for emergency patients with a low probability of bacteremia, which may result in a large waste of resources. At IDWeek 2023, a study reported the implementation of a blood culture algorithm in emergency department patients as a diagnostic stewardship intervention.
Professor Lv Wei: An All-Encompassing Interpretation of Clinical Diagnosis and Treatment Strategies for Late-Diagnosed HIV Patients

Professor Lv Wei: An All-Encompassing Interpretation of Clinical Diagnosis and Treatment Strategies for Late-Diagnosed HIV Patients

This article features an interview with Professor Lv Wei, offering a comprehensive analysis of the clinical diagnosis and treatment strategies for late-presenting HIV patients. This group is a significant challenge in China's HIV/AIDS prevention and treatment efforts due to their higher hospitalization and transmission rates, heavier economic burdens, and poorer long-term prognosis.
Pay attention to the comorbidities of the heart, lungs, and metabolic system in HIV infected individuals

Pay attention to the comorbidities of the heart, lungs, and metabolic system in HIV infected individuals

Anti retroviral therapy (ART) significantly improves the life expectancy of HIV infected individuals. However, in recent years, the incidence rate of cardiovascular diseases and other complications related to obesity, type 2 diabetes, and metabolic syndrome (namely, abdominal obesity, hypertension, elevated triglyceride levels, dyslipidemia, and changes in blood glucose levels) has gradually increased among HIV infected people, which has become a growing concern. The complex interaction between sustained low-level immune activation, ART related metabolic toxicity, and non HIV related risk factors in chronic HIV infection may increase the risk of these comorbidities in HIV infected individuals. At the 19th European Conference on AIDS (EACS 2023), Professor Susanne Dam Nielsen of the University of Copenhagen, Denmark, made a special report on the study of non infectious complications among HIV infected people, focusing on the latest research progress of cardiovascular disease, pulmonary disease and metabolic system disease complications. Our reporter invited Professor Nielsen to conduct an in-depth interview on this topic at the conference.
CVD risks in women living with HIV

CVD risks in women living with HIV

Hi there. My name is Chris Longenecker. I'm a cardiologist at the University of Washington in Seattle, Washington, USA. I specialize in the care of people living with HIV infection. For many years I've run a clinic focused on cardiovascular disease management and prevention of cardiovascular disease for people living with HIV, first in Cleveland, Ohio for many years and now in Seattle.
Advances and Challenges in the Use of Pre-Exposure Prophylaxis (PrEP) and Post-Exposure Prophylaxis (PEP) for HIV

Advances and Challenges in the Use of Pre-Exposure Prophylaxis (PrEP) and Post-Exposure Prophylaxis (PEP) for HIV

With continuous progress in HIV treatment, the mortality rate has significantly decreased, and new infections have stabilized. However, there is still a gap from the 2020 targets set by the United Nations Programme on HIV/AIDS. To control new HIV infections, a comprehensive use of behavioral and biomedical methods, including antiviral drugs for pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP), is crucial. This strategy aims to reduce HIV transmission and control new infections. The 19th European AIDS Conference (EACS 2023) was held in Warsaw, Poland, from October 18 to 20, 2023. At the conference, Professor Jean-Michel Molina from the University of Paris City, Saint Louis and Lariboisière Hospital, shared insights on the application and challenges of HIV PrEP and PEP.

What to start with? A review of current guidelines (EACS, WHO, DHHS)

Hello. My name is Cristiana Oprea. I'm an infectious disease and HIV clinician at Victor Babes Hospital for infectious and tropical diseases in Bucharest, and also an associate professor at Carol Davila University of Medicine and Pharmacy in Bucharest, Romania. I am part of the European AIDS Clinical Society governing board since 2014, and also part of the EuroSida steering committee since 2017.

Integrase Inhibitors Do Not Increase Cardiovascular Event Risk in HIV Patients

This article discusses a significant study presented at the 19th European AIDS Conference (EACS 2023), held in Warsaw, Poland, from October 18-20, 2023. Professor Bernard Surial from the University of Bern in Switzerland shared the results of an international cohort study, which revealed that the use of integrase strand transfer inhibitors (INSTIs) in the treatment of HIV does not increase the risk of cardiovascular events.